To: John Carragher who wrote (403 ) 7/16/1998 1:42:00 PM From: John Carragher Respond to of 798
Home - Yahoo! - Help [ Business | US Market | By Industry | IPO | AP | S&P | International | PRNews | BizWire ] Thursday July 16, 1:18 pm Eastern Time Company Press Release SOURCE: Boston Scientific Corporation Boston Scientific Receives Approval For Radius Stent NATICK, Mass., July 16 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX - news) announced today U.S. Food & Drug Administration (FDA) approval and immediate market release of the Radius(TM), a self-expanding coronary stent system approved for the treatment of coronary artery disease. The Radius stent will be marketed by SCIMED, a division of Boston Scientific, and will be available for commercial sale in lengths of 14mm and 20mm which cover vessel diameters ranging from 2.75mm to 4.25mm. Coronary stents prop open arteries to facilitate blood flow to the heart. The Radius stent is the first self-expanding coronary stent available in the United States. The Radius stent uses a proprietary high performance sheathed delivery system that provides a high degree of deliverability and stent security for procedural safety. The SCORES trial, a randomized clinical trial involving 50 interventional cardiology centers and approximately 1,100 patients, was used as the basis for FDA approval. The trial showed that overall the Radius stent achieved equivalent six month clinical results versus a stainless steel balloon expandable stent. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. SOURCE: Boston Scientific Corporation More Quotes and News: Boston Scientific Corp (NYSE:BSX - news) Related News Categories: medical/pharmaceutical Help Copyright c 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information. Questions or Comments?